Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Connective Tissue Growth Factor Inhibition Enhances Cardiac Repair and Limits Fibrosis After Myocardial Infarction.

Vainio LE, Szabó Z, Lin R, Ulvila J, Yrjölä R, Alakoski T, Piuhola J, Koch WJ, Ruskoaho H, Fouse SD, Seeley TW, Gao E, Signore P, Lipson KE, Magga J, Kerkelä R.

JACC Basic Transl Sci. 2019 Feb 25;4(1):83-94. doi: 10.1016/j.jacbts.2018.10.007. eCollection 2019 Feb.

2.

Denervation-induced skeletal muscle fibrosis is mediated by CTGF/CCN2 independently of TGF-β.

Rebolledo DL, González D, Faundez-Contreras J, Contreras O, Vio CP, Murphy-Ullrich JE, Lipson KE, Brandan E.

Matrix Biol. 2019 Sep;82:20-37. doi: 10.1016/j.matbio.2019.01.002. Epub 2019 Feb 1.

PMID:
30716392
3.

Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology.

de Boer RA, De Keulenaer G, Bauersachs J, Brutsaert D, Cleland JG, Diez J, Du XJ, Ford P, Heinzel FR, Lipson KE, McDonagh T, Lopez-Andres N, Lunde IG, Lyon AR, Pollesello P, Prasad SK, Tocchetti CG, Mayr M, Sluijter JPG, Thum T, Tschöpe C, Zannad F, Zimmermann WH, Ruschitzka F, Filippatos G, Lindsey ML, Maack C, Heymans S.

Eur J Heart Fail. 2019 Mar;21(3):272-285. doi: 10.1002/ejhf.1406. Epub 2019 Feb 4.

4.

Quantitative CT analysis using functional imaging is superior in describing disease progression in idiopathic pulmonary fibrosis compared to forced vital capacity.

Clukers J, Lanclus M, Mignot B, Van Holsbeke C, Roseman J, Porter S, Gorina E, Kouchakji E, Lipson KE, De Backer W, De Backer J.

Respir Res. 2018 Nov 6;19(1):213. doi: 10.1186/s12931-018-0918-5.

5.

Analysis of longitudinal semicontinuous data using marginalized two-part model.

Jaffa MA, Gebregziabher M, Garrett SM, Luttrell DK, Lipson KE, Luttrell LM, Jaffa AA.

J Transl Med. 2018 Nov 6;16(1):301. doi: 10.1186/s12967-018-1674-5.

6.

The inhibition of CTGF/CCN2 activity improves muscle and locomotor function in a murine ALS model.

Gonzalez D, Rebolledo DL, Correa LM, Court FA, Cerpa W, Lipson KE, van Zundert B, Brandan E.

Hum Mol Genet. 2018 Aug 15;27(16):2913-2926. doi: 10.1093/hmg/ddy204.

PMID:
29860398
7.

Role of ADAMTS-12 in Protecting Against Inflammatory Arthritis in Mice By Interacting With and Inactivating Proinflammatory Connective Tissue Growth Factor.

Wei JL, Fu W, Hettinghouse A, He WJ, Lipson KE, Liu CJ.

Arthritis Rheumatol. 2018 Nov;70(11):1745-1756. doi: 10.1002/art.40552. Epub 2018 Sep 24.

PMID:
29750395
8.

Connective tissue growth factor-specific monoclonal antibody inhibits growth of malignant mesothelioma in an orthotopic mouse model.

Ohara Y, Chew SH, Misawa N, Wang S, Somiya D, Nakamura K, Kajiyama H, Kikkawa F, Tsuyuki Y, Jiang L, Yamashita K, Sekido Y, Lipson KE, Toyokuni S.

Oncotarget. 2018 Apr 6;9(26):18494-18509. doi: 10.18632/oncotarget.24892. eCollection 2018 Apr 6.

9.

Vascular Endothelial Cell-Specific Connective Tissue Growth Factor (CTGF) Is Necessary for Development of Chronic Hypoxia-Induced Pulmonary Hypertension.

Pi L, Fu C, Lu Y, Zhou J, Jorgensen M, Shenoy V, Lipson KE, Scott EW, Bryant AJ.

Front Physiol. 2018 Feb 27;9:138. doi: 10.3389/fphys.2018.00138. eCollection 2018.

10.

Plasma Connective Tissue Growth Factor (CTGF/CCN2) Levels Predict Myocardial Infarction in the Veterans Affairs Diabetes Trial (VADT) Cohort.

Hunt KJ, Jaffa MA, Garrett SM, Luttrell DK, Lipson KE, Lopes-Virella MF, Luttrell LM, Jaffa AA; VADT Investigators.

Diabetes Care. 2018 Apr;41(4):840-846. doi: 10.2337/dc17-2083. Epub 2018 Jan 30.

11.

Radiation-induced pulmonary gene expression changes are attenuated by the CTGF antibody Pamrevlumab.

Sternlicht MD, Wirkner U, Bickelhaupt S, Lopez Perez R, Tietz A, Lipson KE, Seeley TW, Huber PE.

Respir Res. 2018 Jan 18;19(1):14. doi: 10.1186/s12931-018-0720-4.

12.

Oncogene addiction and radiation oncology: effect of radiotherapy with photons and carbon ions in ALK-EML4 translocated NSCLC.

Dai Y, Wei Q, Schwager C, Hanne J, Zhou C, Herfarth K, Rieken S, Lipson KE, Debus J, Abdollahi A.

Radiat Oncol. 2018 Jan 5;13(1):1. doi: 10.1186/s13014-017-0947-0.

13.

Inhibition of CTGF ameliorates peritoneal fibrosis through suppression of fibroblast and myofibroblast accumulation and angiogenesis.

Sakai N, Nakamura M, Lipson KE, Miyake T, Kamikawa Y, Sagara A, Shinozaki Y, Kitajima S, Toyama T, Hara A, Iwata Y, Shimizu M, Furuichi K, Kaneko S, Tager AM, Wada T.

Sci Rep. 2017 Jul 14;7(1):5392. doi: 10.1038/s41598-017-05624-2.

14.

Anti-connective tissue growth factor (CTGF/CCN2) monoclonal antibody attenuates skin fibrosis in mice models of systemic sclerosis.

Makino K, Makino T, Stawski L, Lipson KE, Leask A, Trojanowska M.

Arthritis Res Ther. 2017 Jun 13;19(1):134. doi: 10.1186/s13075-017-1356-3.

15.

Effects of CTGF Blockade on Attenuation and Reversal of Radiation-Induced Pulmonary Fibrosis.

Bickelhaupt S, Erbel C, Timke C, Wirkner U, Dadrich M, Flechsig P, Tietz A, Pföhler J, Gross W, Peschke P, Hoeltgen L, Katus HA, Gröne HJ, Nicolay NH, Saffrich R, Debus J, Sternlicht MD, Seeley TW, Lipson KE, Huber PE.

J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djw339.

PMID:
28376190
16.

ERK1/2 directly acts on CTGF/CCN2 expression to mediate myocardial fibrosis in cardiomyopathy caused by mutations in the lamin A/C gene.

Chatzifrangkeskou M, Le Dour C, Wu W, Morrow JP, Joseph LC, Beuvin M, Sera F, Homma S, Vignier N, Mougenot N, Bonne G, Lipson KE, Worman HJ, Muchir A.

Hum Mol Genet. 2016 Jun 1;25(11):2220-2233. Epub 2016 Apr 30.

17.

FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition.

Brenner MC, Krzyzanski W, Chou JZ, Signore PE, Fung CK, Guzman D, Li D, Zhang W, Olsen DR, Nguyen VT, Koo CW, Sternlicht MD, Lipson KE.

Pharm Res. 2016 Aug;33(8):1833-49. doi: 10.1007/s11095-016-1918-0. Epub 2016 Apr 8.

18.

Connective tissue growth factor regulates cardiac function and tissue remodeling in a mouse model of dilated cardiomyopathy.

Koshman YE, Sternlicht MD, Kim T, O'Hara CP, Koczor CA, Lewis W, Seeley TW, Lipson KE, Samarel AM.

J Mol Cell Cardiol. 2015 Dec;89(Pt B):214-22. doi: 10.1016/j.yjmcc.2015.11.003. Epub 2015 Nov 5.

19.

Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors.

Schölch S, Rauber C, Tietz A, Rahbari NN, Bork U, Schmidt T, Kahlert C, Haberkorn U, Tomai MA, Lipson KE, Carretero R, Weitz J, Koch M, Huber PE.

Oncotarget. 2015 Mar 10;6(7):4663-76.

20.

Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer.

Dai Y, Wei Q, Schwager C, Moustafa M, Zhou C, Lipson KE, Weichert W, Debus J, Abdollahi A.

Radiother Oncol. 2015 Feb;114(2):173-81. doi: 10.1016/j.radonc.2014.12.009. Epub 2015 Jan 12.

PMID:
25592111
21.

Connective tissue growth factor inhibition attenuates left ventricular remodeling and dysfunction in pressure overload-induced heart failure.

Szabó Z, Magga J, Alakoski T, Ulvila J, Piuhola J, Vainio L, Kivirikko KI, Vuolteenaho O, Ruskoaho H, Lipson KE, Signore P, Kerkelä R.

Hypertension. 2014 Jun;63(6):1235-40. doi: 10.1161/HYPERTENSIONAHA.114.03279. Epub 2014 Mar 31.

PMID:
24688123
22.

Anti-connective tissue growth factor antibody treatment reduces extracellular matrix production in trabecular meshwork and lamina cribrosa cells.

Wallace DM, Clark AF, Lipson KE, Andrews D, Crean JK, O'Brien CJ.

Invest Ophthalmol Vis Sci. 2013 Dec 2;54(13):7836-48. doi: 10.1167/iovs.13-12494.

PMID:
24204045
23.

Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy.

Morales MG, Gutierrez J, Cabello-Verrugio C, Cabrera D, Lipson KE, Goldschmeding R, Brandan E.

Hum Mol Genet. 2013 Dec 15;22(24):4938-51. doi: 10.1093/hmg/ddt352. Epub 2013 Jul 30.

PMID:
23904456
24.

CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis.

Lipson KE, Wong C, Teng Y, Spong S.

Fibrogenesis Tissue Repair. 2012 Jun 6;5(Suppl 1):S24. doi: 10.1186/1755-1536-5-S1-S24. eCollection 2012.

25.

Development of the first generation c-met kinase inhibitors: beginning of a path to a new treatment for cancer.

Wang X, McMahon G, Lipson KE.

Mol Cancer Ther. 2011 Nov;10(11):2022-3. doi: 10.1158/1535-7163.MCT-11-0714. No abstract available.

26.

Connective tissue growth factor antibody therapy attenuates hyperoxia-induced lung injury in neonatal rats.

Alapati D, Rong M, Chen S, Hehre D, Rodriguez MM, Lipson KE, Wu S.

Am J Respir Cell Mol Biol. 2011 Dec;45(6):1169-77. doi: 10.1165/rcmb.2011-0023OC. Epub 2011 Jun 9.

PMID:
21659659
27.

Potentiation of the anti-tumor effects of imidazoquinoline immune response modifiers by cyclophosphamide.

Dumitru CD, Antonysamy MA, Tomai MA, Lipson KE.

Cancer Biol Ther. 2010 Jul 15;10(2):155-65. Epub 2010 Jul 26.

PMID:
20519933
28.

Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model.

Li M, Abdollahi A, Gröne HJ, Lipson KE, Belka C, Huber PE.

Radiat Oncol. 2009 Dec 21;4:66. doi: 10.1186/1748-717X-4-66.

29.

Connective tissue growth factor promotes fibrosis downstream of TGFbeta and IL-6 in chronic cardiac allograft rejection.

Booth AJ, Csencsits-Smith K, Wood SC, Lu G, Lipson KE, Bishop DK.

Am J Transplant. 2010 Feb;10(2):220-30. doi: 10.1111/j.1600-6143.2009.02826.x. Epub 2009 Sep 25.

30.

NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model.

Dumitru CD, Antonysamy MA, Gorski KS, Johnson DD, Reddy LG, Lutterman JL, Piri MM, Proksch J, McGurran SM, Egging EA, Cochran FR, Lipson KE, Tomai MA, Gullikson GW.

Cancer Immunol Immunother. 2009 Apr;58(4):575-87. doi: 10.1007/s00262-008-0581-7. Epub 2008 Sep 13.

PMID:
18791716
31.

Comparison of human B cell activation by TLR7 and TLR9 agonists.

Hanten JA, Vasilakos JP, Riter CL, Neys L, Lipson KE, Alkan SS, Birmachu W.

BMC Immunol. 2008 Jul 24;9:39. doi: 10.1186/1471-2172-9-39.

32.

TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN.

Inglefield JR, Dumitru CD, Alkan SS, Gibson SJ, Lipson KE, Tomai MA, Larson CJ, Vasilakos JP.

J Interferon Cytokine Res. 2008 Apr;28(4):253-63. doi: 10.1089/jir.2007.0097.

PMID:
18439103
33.

Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.

Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A, Huber PE.

Clin Cancer Res. 2008 Apr 1;14(7):2210-9. doi: 10.1158/1078-0432.CCR-07-1893.

34.

SU11657 enhances radiosensitivity of human meningioma cells.

Milker-Zabel S, Zabel-du Bois A, Ranai G, Trinh T, Unterberg A, Debus J, Lipson KE, Abdollahi A, Huber PE.

Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1213-8. doi: 10.1016/j.ijrobp.2007.11.041. Epub 2008 Jan 30.

PMID:
18234428
35.

Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists.

Birmachu W, Gleason RM, Bulbulian BJ, Riter CL, Vasilakos JP, Lipson KE, Nikolsky Y.

BMC Immunol. 2007 Oct 12;8:26.

36.

Resiquimod and other immune response modifiers as vaccine adjuvants.

Tomai MA, Miller RL, Lipson KE, Kieper WC, Zarraga IE, Vasilakos JP.

Expert Rev Vaccines. 2007 Oct;6(5):835-47. Review.

PMID:
17931162
37.

Inhibition of in vitro tumor cell proliferation by cytokines induced by combinations of TLR or TLR and TCR agonists.

Ghosh TK, Mickelson DJ, Lipson KE, Alkan SS.

Int Immunopharmacol. 2007 Nov;7(11):1471-82. Epub 2007 Jun 26.

PMID:
17761351
38.

TLR-TLR cross talk in human PBMC resulting in synergistic and antagonistic regulation of type-1 and 2 interferons, IL-12 and TNF-alpha.

Ghosh TK, Mickelson DJ, Solberg JC, Lipson KE, Inglefield JR, Alkan SS.

Int Immunopharmacol. 2007 Aug;7(8):1111-21. Epub 2007 May 4.

PMID:
17570328
39.

Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec).

Oertel S, Krempien R, Lindel K, Zabel A, Milker-Zabel S, Bischof M, Lipson KE, Peschke P, Debus J, Abdollahi A, Huber PE.

Strahlenther Onkol. 2006 Jul;182(7):400-7.

PMID:
16826359
40.

Small molecule receptor tyrosine kinase inhibitor of platelet-derived growth factor signaling (SU9518) modifies radiation response in fibroblasts and endothelial cells.

Li M, Ping G, Plathow C, Trinh T, Lipson KE, Hauser K, Krempien R, Debus J, Abdollahi A, Huber PE.

BMC Cancer. 2006 Mar 24;6:79.

41.

Adventitial microvessel formation after coronary stenting and the effects of SU11218, a tyrosine kinase inhibitor.

Cheema AN, Hong T, Nili N, Segev A, Moffat JG, Lipson KE, Howlett AR, Holdsworth DW, Cole MJ, Qiang B, Kolodgie F, Virmani R, Stewart DJ, Strauss BH.

J Am Coll Cardiol. 2006 Mar 7;47(5):1067-75. Epub 2006 Feb 9.

42.

Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy.

Abdollahi A, Griggs DW, Zieher H, Roth A, Lipson KE, Saffrich R, Gröne HJ, Hallahan DE, Reisfeld RA, Debus J, Niethammer AG, Huber PE.

Clin Cancer Res. 2005 Sep 1;11(17):6270-9.

43.

Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy.

Huber PE, Bischof M, Jenne J, Heiland S, Peschke P, Saffrich R, Gröne HJ, Debus J, Lipson KE, Abdollahi A.

Cancer Res. 2005 May 1;65(9):3643-55.

44.

Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis.

Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F, Lee LB, McMahon G, Gröne HJ, Lipson KE, Huber PE.

J Exp Med. 2005 Mar 21;201(6):925-35.

45.

The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression.

Litz J, Sakuntala Warshamana-Greene G, Sulanke G, Lipson KE, Krystal GW.

Lung Cancer. 2004 Dec;46(3):283-91.

PMID:
15541812
46.

Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells.

Bischof M, Abdollahi A, Gong P, Stoffregen C, Lipson KE, Debus JU, Weber KJ, Huber PE.

Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1220-32.

PMID:
15519795
47.

The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.

Berthou S, Aebersold DM, Schmidt LS, Stroka D, Heigl C, Streit B, Stalder D, Gruber G, Liang C, Howlett AR, Candinas D, Greiner RH, Lipson KE, Zimmer Y.

Oncogene. 2004 Jul 8;23(31):5387-93.

PMID:
15064724
48.

Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.

Abdollahi A, Lipson KE, Sckell A, Zieher H, Klenke F, Poerschke D, Roth A, Han X, Krix M, Bischof M, Hahnfeldt P, Grone HJ, Debus J, Hlatky L, Huber PE.

Cancer Res. 2003 Dec 15;63(24):8890-8.

49.

Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion.

Wang X, Le P, Liang C, Chan J, Kiewlich D, Miller T, Harris D, Sun L, Rice A, Vasile S, Blake RA, Howlett AR, Patel N, McMahon G, Lipson KE.

Mol Cancer Ther. 2003 Nov;2(11):1085-92.

50.

A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.

Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R, Lipson KE, Ramphal J, Do S, Cui JJ, Cherrington JM, Mendel DB.

Cancer Res. 2003 Nov 1;63(21):7345-55.

Supplemental Content

Loading ...
Support Center